Sheng-Lan Wang1, Xin-Yan Zhu2, Dong-Wei Zhang1, Zhao-Jie Zhang1, Heng-Jun Gao1, Chang-Qing Yang1. 1. Division of Gastroenterology and Digestive Diseases Institute, Shanghai Tongji Hospital, Tongji University School of Medicine Shanghai 200065, China. 2. Division of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine Shanghai 200120, China.
Abstract
BACKGROUND: Portal hypertension is one of the death reasons for the liver cirrhosis patients. The oxidative stress is related to the occurrence and development of portal hypertension in cirrhosis. Malondialdehyde (MDA), one of the lipid peroxides, increases substantially in cirrhotic patients. AIMS: To evaluate the relevance between the MDA level and portal hypertension in cirrhotic patients. METHODS: 60 liver cirrhotic patients and 30 healthy controls were enrolled. The plasma MDA level and general blood tests including ALT, AST, ALB, total bilirubin, and platelet were measured. All people enrolled accepted endoscopic examination and B-Ultrasound check to evaluate the severity of portal hypertension. RESULTS: The MDA plasma level of cirrhotic patients was significantly higher than the controls (P<0.001) and increased significantly accompanied by the severity of liver fibrosis and portal hypertension (P<0.01). Further, the plasma MDA level of cirrhotic patients was significantly correlated with Child-Pugh classification of cirrhosis (r=0.820, P<0.001), the degree of esophageal varices (r=0.857, P<0.001) and the width of portal vein (r=0.652, P<0.001). The ROC curve analyses showed that the plasma MDA level is a strong predictor of liver cirrhosis and portal hypertension. CONCLUSIONS: Plasma MDA level may correlate with the severity of portal hypertension in cirrhotic patients.
BACKGROUND: Portal hypertension is one of the death reasons for the liver cirrhosispatients. The oxidative stress is related to the occurrence and development of portal hypertension in cirrhosis. Malondialdehyde (MDA), one of the lipid peroxides, increases substantially in cirrhotic patients. AIMS: To evaluate the relevance between the MDA level and portal hypertension in cirrhotic patients. METHODS: 60 liver cirrhoticpatients and 30 healthy controls were enrolled. The plasma MDA level and general blood tests including ALT, AST, ALB, total bilirubin, and platelet were measured. All people enrolled accepted endoscopic examination and B-Ultrasound check to evaluate the severity of portal hypertension. RESULTS: The MDA plasma level of cirrhotic patients was significantly higher than the controls (P<0.001) and increased significantly accompanied by the severity of liver fibrosis and portal hypertension (P<0.01). Further, the plasma MDA level of cirrhotic patients was significantly correlated with Child-Pugh classification of cirrhosis (r=0.820, P<0.001), the degree of esophageal varices (r=0.857, P<0.001) and the width of portal vein (r=0.652, P<0.001). The ROC curve analyses showed that the plasma MDA level is a strong predictor of liver cirrhosis and portal hypertension. CONCLUSIONS: Plasma MDA level may correlate with the severity of portal hypertension in cirrhotic patients.
Authors: F Trevisani; P Caraceni; M Simoncini; M Micati; M Domenicali; F Dazzani; A Zambruni; C Stefanelli; G Grazi; B Nardo; C Guarnieri; M Bernardi Journal: Dig Liver Dis Date: 2002-04 Impact factor: 4.088
Authors: Lana J Dixon; Sinead M Hughes; Keith Rooney; Aine Madden; Adrian Devine; William Leahey; Welby Henry; G Dennis Johnston; Gary E McVeigh Journal: Am J Hypertens Date: 2005-06 Impact factor: 2.689
Authors: Sanjiv K Jain; Philip W Pemberton; Alexander Smith; Raymond F T McMahon; Peter C Burrows; Ali Aboutwerat; Thomas W Warnes Journal: J Hepatol Date: 2002-06 Impact factor: 25.083